This signature becomes even more significantly representative of our experimental setting: CRC patients whose samples were collected in TCGA database with demonstrated high CEACAM1/low EPHA2/low CEACAM6 expression benefited from a much better prognosis and longer survival. The gene discussed is EPHA2; the disease is colorectal carcinoma.